Teclistamab
Cytokine Release Syndrome
Naresh Bummamonoclonal_antibodyPhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
6 Active assets in the Cytokine Release Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Siltuximab Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | B |
Anakinra Ann & Robert H Lurie Children's Hospital of Chicago | Phase 2 | B |
Axicabtagene Ciloleucel Marcela V. Maus, M.D.,Ph.D. | Phase 2 | B |
Infliximab Naresh Bumma | Phase 2 | CCC |
Talquetamab Naresh Bumma | Phase 2 | CCC |
CTO1681 CytoAgents, Inc. | Phase 1/2 | CC |
Epcoritamab Taylor Brooks | Phase 1 | CC |
Fentanyl University of Guadalajara | N/A | D |
Same molecule, other indications
Teclistamab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →